OpGen (NASDAQ:OPGN) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN) in a research report issued on Thursday. The brokerage set a “sell” rating on the medical research company’s stock.

OpGen Trading Up 2.0 %

OPGN stock opened at $0.72 on Thursday. OpGen has a 12-month low of $0.66 and a 12-month high of $9.90. The business’s 50-day moving average is $1.57 and its 200 day moving average is $2.10.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.